COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results of the Prospective Phase 2 Trial.
OBJECTIVE
To investigate the effect of intensity modulated radiation therapy (IMRT) and dose-escalated carbon ion (C12) therapy in adenoid cystic carcinoma (ACC) and other malignant salivary gland tumors (MSGTs) of the head and neck.


METHODS
COSMIC (combined treatment of malignant salivary gland tumors with intensity modulated radiation therapy and carbon ions) is a prospective phase 2 trial of 24 Gy(RBE) C12 followed by 50 Gy IMRT in patients with pathologically confirmed MSGT. The primary endpoint is mucositis Common Terminology Criteria grade 3; the secondary endpoints are locoregional control (LC), progression-free survival (PFS), overall survival (OS), and toxicity. Toxicity was scored according to the Common Terminology Criteria for Adverse Events version 3; treatment response was scored according to Response Evaluation Criteria in Solid Tumors 1.1.


RESULTS
Between July 2010 and August 2011, 54 patients were accrued, and 53 were available for evaluation. The median follow-up time was 42 months; patients with microscopically incomplete resections (R1, n = 20), gross residual disease (R2, n = 17), and inoperable disease (n = 16) were included. Eighty-nine percent of patients had ACC, and 57% had T4 tumors. The most common primary sites were paranasal sinus (34%), submandibular gland, and palate. At the completion of radiation therapy, 26% of patients experienced grade 3 mucositis, and 20 patients reported adverse events of the ear (38%). The most common observed late effects were grade 1 xerostomia (49%), hearing impairment (25%, 2% ipsilateral hearing loss), and adverse events of the eye (20%), but no visual impairment or loss of vision. Grade 1 central nervous system necrosis occurred in 6%, and 1 grade 4 ICA hemorrhage without neurologic sequelae. The best response was 54% (complete response/partial remission). At 3 years, the LC, PFS, and OS were 81.9%, 57.9%, and 78.4%, respectively. No difference was found regarding resection status. The most common site of failure was distant (55%). Local relapse was predominantly in field (79%).


CONCLUSIONS
Treatment was tolerated, with moderate acute and late toxicity. The LC at 3 years was promising. No significant difference could be shown regarding resection status; hence, extensive and mutilating surgical procedures should be rediscussed. Further dose escalation may be limited in view of potential vascular adverse events.
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. Electronic address: alexdjensen@gmx.de.
Alexandra D
AD
Jensen
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.
Anna V
AV
Nikoghosyan
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.
Karen
K
Lossner
Heidelberg Ion Beam Therapy Centre, Heidelberg, Germany.
Thomas
T
Haberer
Heidelberg Ion Beam Therapy Centre, Heidelberg, Germany.
Oliver
O
Jäkel
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.
Marc W
MW
Münter
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.
Jürgen
J
Debus
D000328:Adult; D000368:Aged; D002250:Carbon Radioisotopes / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058958:Organs at Risk; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*; D012468:Salivary Gland Neoplasms / Q000532:radiotherapy*
D002250:Carbon Radioisotopes